• Title/Summary/Keyword: stable disease(SD)

Search Result 35, Processing Time 0.03 seconds

A Case Report on the Patient of Malignant Melanoma at Right Maxilla with the Treatment of Bee Venom Phamacopuncture (봉독약침을 시행한 우측상악동의 악성 흑색종 환자에 대한 증례보고)

  • Bang, Sun-Hwi;Yoo, Hwa-Seung
    • Journal of Pharmacopuncture
    • /
    • v.10 no.2 s.23
    • /
    • pp.99-105
    • /
    • 2007
  • Objectives : It is the aim of this study to derive lurker studies evaluating the effectiveness of bee-venom phamacopuncture on malignant melanoma patients. We present a patient of malignant melanoma at right maxilla who survives over one year with stable disease (SD) by the treatment of Bee Venom Phamacopuncture (BVP). Methods : We followed the treatment and examination. We prescribed to the patient what to be taken 1.5cc BVP once a day. Picture series, Head series were followed-up and Neck computed tomography (CT) and positron emission tomography computed tomography (PET CT) were performed to evaluate the therapeutic efficacy. Results : The patient survives over one year and continued stable disease over 6 months. Picture series, Head series X-ray, neck CT and PET CT were shown no interval change. Conclusion : This case may give us the possibility that BVP offers potential benefits for patients with malignant melanoma.

Two Cases of Non-Small Cell Lung Cancer Treated with Intravenous Cultivated Wild Ginseng Pharmacopuncture (산삼약침 혈맥주입을 시행한 비소세포성폐암 환자 2례)

  • Bang, Sun-Hwi;Kwon, Ki-Rok;Yoo, Hwa-Seung
    • Journal of Pharmacopuncture
    • /
    • v.11 no.2
    • /
    • pp.13-19
    • /
    • 2008
  • Objectives To investigate the therapeutic effects of intravenous cultivated wild ginseng(Panax ginseng C.A. Meyer) pharmacopuncture(CWGP) in treating patients with non-small cell lung cancer(NSCLC). Design Prospective case series. Setting This study was conducted at the East-West Cancer Center of Dunsan Oriental Hospital, Daejeon University. Patients Two non-small cell lung cancer patients. Intervention Two non-small cell lung cancer patients were injected CWGP(20mL/day) mixed with 0.9% normal saline(100mL) intravenously. Each patient received a total of 16 and 9 cycles, respectively. One cycle is composed of 14 days. Outcome Measures The effect of intravenous CWGP was measured by scanning with computed tomography(CT) after every 2 cycle and Positron emission tomography- computed tomography(PET/CT) after every 6 cycles. Response and progression was evaluated using the Response Evaluation Criteria in Solid Tumors(RECIST) Committee classification of complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD). Results They were treated with intravenous CWGP for 8 and 5 months respectively. time later, each tumor remains stable disease(SD). Conclusion These cases may give us a possibility that intravenous CWGP offers potential benefits for non-small cell lung cancer patients.

Case Series of Advanced Non-Small Cell Lung Cancer Patients Treated with Hang-Am Plus (진행성 비소세포성 폐암환자에 대한 항암플러스의 치료효능 : 연속증례보고)

  • Zheng, Hong-Mei;Yoon, Jeung-Won;Lee, Yeon-Weol;Cho, Chong-Kwan;Oh, Dal-Seok;Yoo, Hwa-Seung
    • The Journal of Internal Korean Medicine
    • /
    • v.32 no.1
    • /
    • pp.113-120
    • /
    • 2011
  • Objectives : A case series was conducted to investigate the therapeutic effects of Hang-Am Plus (HAP) on the tumor response and HRQoL (Health Related Quality of Life) in advanced non-small cell lung cancer (NSCLC) patients. Methods : Three patients were given 1,000-2,000 mg of HAP, three times a day (daily total dosage of 3,000-6,000 mg/day) for 12 weeks. Results : After the 3 month administration with HAP, three patients showed stable disease (SD) condition according to the chest computed tomography (CT), and two of the patients reported a decrease in pain levels. Conclusions : The observed NSCLC cases suggest treatment with HAP may be related to the observed tumor growth inhibition and pain reduction.

Case Series of Advanced or Metastatic Gallbladder Cancer Patients Treated with Hang-Am-Dan (항암단 투여로 호전된 진행성 또는 전이성 담낭암 연속환자증례)

  • Kim, Kyung-Soon;Yoo, Hwa-Seung;Jung, Tae-Young;Lee, Yeon-Weol;Cho, Chong-Kwan
    • The Journal of Internal Korean Medicine
    • /
    • v.31 no.3
    • /
    • pp.667-674
    • /
    • 2010
  • Objective : To investigate the therapeutic effects of Hang-Am-Dan(HAD) on gallbladder cancer patients. Method : We prescribed HAD three times a day(3,000-6,000 mg/day) during a treatment period of 8 and 34 months respectively. Computed tomography(CT) was taken to evaluate the therapeutic efficacy. Results : Two patients diagnosed with gallbladder cancer were recommended to go through chemotherapy. However, they refused the standard regimen due to their old age and the fear of side effects, and chose to go with Oriental medicine treatments instead. The patients were treated for 8 and 34 months respectively. Each patient showed stable disease(SD) state during the treatment period. Conclusion : According to these cases, it could be concluded that HAD may offer potential benefits in treating gallbladder cancer patients.

Case Series of Advanced Non-small Cell Lung Cancer Patients Treated with Hang-Am-Plus (항암플러스 투여로 호전된 진행성 비소세포성 폐암 연속환자증례)

  • Kim, Kyung-Soon;Jung, Tae-Young;Yoo, Hwa-Seung;Lee, Yeon-Weol;Cho, Chong-Kwan
    • The Journal of Internal Korean Medicine
    • /
    • v.30 no.4
    • /
    • pp.893-900
    • /
    • 2009
  • Objective : To investigate the therapeutic effects of Hang-Am-Plus (HAP) on advanced non-small cell lung cancer (NSCLC) patients. Method : We prescribed HAP three times a day (3,000-6,000 mg/ day) during the treatment period (8 - 24 months). Computed tomography (CT) was performed to evaluate the therapeutic efficacy. Results : Four patients who were diagnosed with NSCLC were recommended chemotherap y, but refused it because of old age, side effects, or treatment failure, and instead sought oriental medicinal therapy. They were treated around 12 months. The patients showed stable disease (SD) state for 5 months, 3 months, 19 months and 3 months, respectively. Conclusion : These four cases may give us the possibility that HAP offers potential benefits for non-small cell lung cancer patients.

  • PDF

A Case Report of Pancreatic Cancer Treated With Lymph Node Metastasis (림프절 전이를 동반한 췌장암환자 1례에 대한 보고)

  • Bang, Sun-Hwi;Lee, Jong-Hoon;Cho, Jung-Hyo;Lee, Yeon-Weol;Son, Chang-Gue;Cho, Chong-Kwan;Yoo, Hwa-Seung
    • The Journal of Internal Korean Medicine
    • /
    • v.28 no.4
    • /
    • pp.948-955
    • /
    • 2007
  • Objectives : We present a case of pancreatic carcinoma patient with lymph node metastasis. Methods : We analyzed the medical record of a pancreatic carcinoma patient with lymph node metastasis who had been treated with traditional Korean medicine from 2006 until 2007. He complained of abdominal pain, dyspepsia and anorexia. We prescribed him HAD, PSM, BKH and other oriental medicines. Results : For 18 months he was treated with oriental medicine. Over this time, the pancreatic tumor remains stable disease (SD) and most symptoms have disappeared. Cconclusions : When it comes to the therapeutic effects, it could be suggested that oriental medicine has effects on keeping SD and improving symptoms.

  • PDF

A Case Report for Recurred Squamous Cell Lung Carcinoma Treated with Hang-Am-Dan : 7-year follow-up (항암단을 투여한 재발성 편평상피폐암 환자에 대한 7년간의 추적조사)

  • Yoo, Seung-Hu;Yoo, Hwa-Seung;Cho, Chong-Kwan;Lee, Yeon-Weol
    • The Journal of Internal Korean Medicine
    • /
    • v.28 no.2
    • /
    • pp.385-390
    • /
    • 2007
  • Objective : The aim of the present study is to derive further studies evaluating the effectiveness of oriental medical treatment on recurred squamous cell carcinoma of the lung. We present a case of recurred squamous cell lung carcinoma patient who has survived more than 7 years. Method : We followed all treatments and examinations. We prescribed the patient take Hang-Am-Dan (HAD) three times a day for 6 years. Computed tomography (CT) was performed to evaluate the therapeutic efficacy. Results : The patient has survived for over 7 years. CT showed stable state (SD). Conclusion : This case may give us a possibility of that oriental medical treatment offers potential benefits for patients with recurred squamous cell lung carcinoma.

  • PDF

Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer

  • Fang, Ying;Wang, Li;Xia, Guo-Hao;Shi, Mei-Qi
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.17
    • /
    • pp.7453-7457
    • /
    • 2014
  • Objective: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). Methods: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel $125mg/m^2$ on day 1 and day 8, cisplatin $75mg/m^2$ on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. One cycle of treatment was 3 weeks, and at least two were completed in each case. Results: Of the 40 patients who participated in the study, 25 achieved partial responses (PR), 12 reached a stage of stable disease (SD), and 3 suffered progressive disease (PD). The overall response rate (ORR) was 62.5% and the disease control rate (DCR) was 92.5%. Of the 20 patients without surgery or radiotherapy, 10 achieved PR, 7 reached a stage of SD, and 3 PD. The ORR was 50.0% and the DCR was 85.0%. The median progression-free survival time (PFS) of patients without surgery or radiotherapy was 5.0 months. Of the 20 patients receiving surgery or radiotherapy, 15 had PR and 5 p had SD, with an ORR of 75.0% and a DCR of 85.0%. Specifically, the DDP arm demonstrated a significantly higher ORR than the CBP arm (100%vs 54.5%, P<0.05). Common treatment related adverse events were myelosuppression, gastrointestinal response, baldness and neurotoxicity, most of which were grade 1 to 2. Conclusion: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotheraphy for stage III/IV squamous NSCLC, and its adverse effects are tolerable.

Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers

  • Qian, Ting;Huang, Xin-En
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.11
    • /
    • pp.4791-4795
    • /
    • 2015
  • Purpose: This study was conducted to observe the efficacy and safety of pemetrexed based chemotherapy in treating patients with locally advanced or metastatic cancers as first-line, second-line or third-line therapy. Materials and Methods: From May 2011 to January 2015, we recruited 29 patients with advanced breast cancer, 19 patients with advanced ovary cancer, 17 patients with advanced esophageal cancer,5 patients with advanced gallbladder cancer,5 patients with advanced cervical cancer and 1 patient with advanced tongue cancer in Jiangsu Cancer Hospital and Research Institute.All of them were pathologically confirmed and treated with pemetrexed based chemotherapy. After two cycles of treatment,efficacy and safety can be evaluated. Results: For pemetrexed based regimens,including 76 patients with 6 kinds of advanced cancer were considered eligible for inclusion. Complete remission represents CR, partial remission represents PR, stable disease represents SD, progressive disease represents PD. Among 29 patients with advanced breast cancer, 4 patients chose pemetrexed based regimens as second-line treatment,1 of them was PR,the other 3 got SD. The last 25 patients made use of this chemotherapy as third-line treatment, except one patient could not be assessed, 2 of them got PR,6 of them got SD,the remaining 16 of them finally were PD.19 patients with advanced ovary cancer,5 patients used this regimens as second-line treatment, 3 of them got PD,the remaining patients got SD, respectively. The last 14 patients made use of pemetrexed based regimens as third-line treatment,. RR (CR+PR) was 28.5%. Among 17 patients with advanced esophageal cancer, 2 patients made use of pemetrexed based regimens as first-line treatment,both of them got PR.4 of them used this chemotherapy as second-line regimen, except 2 patients could not be assessed,the remaining 2 was PD at last. The last 11 patients was third-line users, RR (CR+PR) was 18.2%. Among 5 patients with advanced gallbladder cancer, pemetrexed based regimens was used in 1 patient as first-line treatment and 1 patient as second-line treatment. The curative effect was SD and PD, respectively. 3 patients accepted pemetrexed based regimens as third-line treatment, 2 of them got PD as results and another was SD. Among 5 patients with advanced cervical cancer, just 1 patient adopted pemetrexed based regimens as first-line treatment, whose curative effect was PR.2 patients chose this chemotherapy regimens as second-line treatment. Both of them got PD as their consequence. The last 2 patients made use of the regimens as third-line treatment, the effect of them was PD and SD, respectively. The one who with advanced tongue cancer, pemetrexed based regimens was used as second-line treatment, and the consequence was PD. About 71.1% patients experienced bone marrow suppression. Among them, 5 patients reached 4 grade. Other toxicity of pemetrexed were neurotoxicity, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-based treatment. Conclusions: Pemetrexed based chemotherapy has considerable effect in patients with advanced cancers such as breast cancer,esophageal cancer and ovary cancer. More randomly clinical trials are needed to verify the results.

Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases

  • Agrawal, Sushma;Mohan, Lalit;Mourya, Chandan;Neyaz, Zafar;Saxena, Rajan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.4
    • /
    • pp.2137-2140
    • /
    • 2016
  • Background: Gall bladder cancer (GBC) usually presents as unresectable or metastatic disease. We conducted a feasibility study to evaluate the effect of neoadjuvant therapy (NAT) on radiologic downstaging and resectability in unresectable GBC cases. Materials and Methods: Patients with locally advanced disease were treated with chemoradiotherapy [CTRT] ( external radiotherapy (45Gy) along with weekly concurrent cisplatin $35mg/m^2$ and 5-FU 500 mg) and those with positive paraaortic nodes were treated with neoadjuvant chemotherapy [NACT (cisplatin $25mg/m^2$ and gemcitabine $1gm/m^2$ day 1 and 8, 3 weekly for 3 cycles). Radiological assessment was according to RECIST criteria by evaluating downstaging of liver involvement and lymphadenopathy into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Results: A total of 40 patients were evaluated from January 2012 to December 2014 (CTRT=25, NACT=15). Pretreatment CT scans revealed involvement of hilum (19), liver infiltration (38), duodenum involvement (n=22), colon involvement (n=11), N1 involvement (n=11), N2 disease (n=8), paraaortic LN (n=15), and no lymphadenopathy (n=6). After neoadjuvant therapy, liver involvement showed CR in 11(30%), PR in 4 (10.5%), SD in 15 (39.4%) and lymph node involvement showed CR in 17 (50%), PR in 6 (17.6%), SD in 4 (11.7 %). Six patients (CTRT=2, NACT=4) with 66.6 % and 83% downstaging of liver and lymphnodes respectively underwent extended cholecystectomy. There was 16.6 % and 83.3% rates of histopathological CR of liver and lymph nodes. All resections were R0. Conclusions: Neoadjuvant therapy in unresectable gall bladder cancer results in a 15% resectability rate. This approach has a strong potential in achieving R0 and node negative disease. Radiologic downstaging (CR+PR) of liver involvement is 40.5% and lymphadenopathy is 67.5%. Nodal regression could serve as a predictor of response to neoadjuvant therapy.